Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 2 completed trials

    Completion Rate
    100%(2/2)
    Active Trials
    0(0%)
    Results Posted
    0%(0 trials)

    Phase Distribution

    Phase 1
    4
    100%

    Phase Distribution

    4

    Early Stage

    0

    Mid Stage

    0

    Late Stage

    Phase Distribution4 total trials
    Phase 1Safety & dosage
    4(100.0%)

    Highest Phase Reached

    Phase 1

    Trial Status & Enrollment

    Completion Rate

    66.7%

    2 of 3 finished

    Non-Completion Rate

    33.3%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    4

    all time

    Status Distribution
    Completed(2)
    Terminated(1)
    Other(1)

    Detailed Status

    Completed2
    Suspended1
    Withdrawn1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    4
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 1

    Trials by Phase

    Phase 14 (100.0%)

    Trials by Status

    completed250%
    suspended125%
    withdrawn125%

    Recent Activity

    0 active trials
    Showing 4 of 4
    completedphase_1

    Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia

    NCT00021983
    withdrawnphase_1

    BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

    NCT00024115
    completedphase_1

    BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma

    NCT00126646
    suspendedphase_1

    BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

    NCT00077493

    Clinical Trials (4)

    Showing 4 of 4 trials
    NCT00021983Phase 1

    Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia

    Completed
    NCT00024115Phase 1

    BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

    Withdrawn
    NCT00126646Phase 1

    BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma

    Completed
    NCT00077493Phase 1

    BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

    Suspended

    All 4 trials loaded

    Drug Details

    Intervention Type
    Varies by study
    Total Trials
    4